<p>HM Payson  Co. 在最近向证券交易委员会提交的文件中表示，在第三季度将其在诺华制药（NYSE:NVS - 免费报告）的持股增加了 306.6%。该基金在季度内购买了额外的 10,000 股后，持有该公司 13,262 股股票。HM Payson  Co. 在诺华的持股在最近的报告期末价值为 1,701,000 美元。</p>
<ul>
<li>诺华的月球计划癌症疗法可能成为未来的增长驱动力</li>
</ul>
<p>其他几家大型投资者也买卖了该公司的股票。Keybank National Association OH 在第二季度将其在诺华的持股提高了 13.2%。Keybank National Association OH 目前持有 49,377 股该公司的股票，价值为 5,975,000 美元，在此期间又购买了 5,742 股。Sonora Investment Management Group LLC 在第二季度获得了诺华的新股份，价值为 266,000 美元。Cypress Capital Group 在第二季度将其在诺华的持股提高了 84.1%。Cypress Capital Group 目前持有 5,776 股该公司的股票，价值为 699,000 美元，在上个季度又购买了 2,638 股。Focus Partners Wealth 在第一季度将其在诺华的持股提高了 16.8%。Focus Partners Wealth 目前持有 47,548 股该公司的股票，价值为 5,311,000 美元，在此期间又购买了 6,849 股。最后，CW Advisors LLC 在第二季度将其在诺华的持股提高了 52.7%。CW Advisors LLC 目前持有 75,340 股该公司的股票，价值为 9,117,000 美元，在此期间又购买了 26,009 股。13.12% 的股票由机构投资者和对冲基金持有。</p>
<h2>诺华股票下跌 0.1%</h2>
<p>NYSE:NVS 的股票周二开盘价为 139.09 美元。该公司的债务与股本比率为 0.50，速动比率为 0.68，流动比率为 0.88。诺华制药的 52 周低点为 96.91 美元，52 周高点为 140.18 美元。该公司的 50 日简单移动平均线为 130.72 美元，200 日简单移动平均线为 125.69 美元。该公司的市值为 2938.2 亿美元，市盈率为 19.00，PEG 比率为 1.97，贝塔值为 0.52。</p>
<ul>
<li>三只在美国投资超过 1000 亿美元的大型制药股</li>
</ul>
<p>诺华（NYSE:NVS - 获取免费报告）最近于 10 月 28 日发布了其财报。该公司报告本季度每股收益为 2.25 美元，低于分析师一致预期的 2.26 美元，差额为 0.01 美元。诺华的股本回报率为 41.21%，净利润率为 26.49%。该公司本季度的收入为 143.6 亿美元，而分析师预期为 137 亿美元。在去年同期，该公司每股收益为 2.06 美元。与去年同期相比，诺华本季度的收入增长了 8.5%。整体来看，研究分析师预测诺华制药在当前财政年度将发布 8.45 美元的每股收益。</p>
<h2>分析师评级变动</h2>
<p>NVS 最近成为多份分析师报告的主题。HC Wainwright 在 10 月 27 日的报告中将诺华的评级下调至 “中性”。Weiss Ratings 在 12 月 22 日的研究报告中重申了对诺华股票的 “买入（b）” 评级。Cowen 在 11 月 10 日的报告中重申了对诺华股票的 “持有” 评级。美国银行在 11 月 25 日的研究报告中将诺华的评级从 “中性” 上调至 “买入”。最后，摩根大通在 12 月 8 日的研究报告中将诺华的评级从 “中性” 上调至 “增持”。一位投资分析师对该股票给予了强烈买入评级，五位给予了买入评级，六位给予了持有评级，三位给予了卖出评级。根据 MarketBeat.com 的数据，该公司目前的平均评级为 “持有”，平均目标价为 119.75 美元。</p>
<ul>
<li>三只可能在市场波动后飙升的动量股</li>
</ul>
<p><strong>获取我们关于诺华的最新报告</strong></p>
<h2>诺华简介</h2>
<p>（免费报告）</p>
<p>诺华是一家总部位于巴塞尔的瑞士跨国制药公司，专注于研究、开发、生产和商业化处方药及相关医疗产品。诺华通过 1996 年 Ciba-Geigy 与 Sandoz 的合并而成立，业务遍及全球，致力于将治疗药物从发现阶段通过临床开发推向全球商业市场。</p>
<p>该公司的活动集中在多个治疗领域的创新药物上，包括肿瘤学、免疫学、心血管和代谢疾病、神经科学和眼科，以及生物制剂、细胞和基因疗法等先进疗法的能力。</p>
<h2>精选文章</h2>
<ul>
<li>五只我们更看好的股票超过诺华</li>
<li>华尔街股票挑选者评选 2026 年第一只股票</li>
<li>请勿删除，立即阅读</li>
<li>家族信托如何帮助保护您的财富</li>
<li>您的 “出生权索赔” 刚刚被激活</li>
<li>在 2026 年 1 月 1 日之前购买这只 2 美元的黄金股票</li>
</ul>
<p><strong>想看看其他对冲基金持有的 NVS 吗？</strong> 访问 HoldingsChannel.com 获取诺华制药（NYSE:NVS - 免费报告）的最新 13F 文件和内部交易。</p>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UWU3ltYm9sPU5WUw?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UWU3ltYm9sPU5WUw"/></p>
<p><em>此即时新闻提醒由叙述科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或评论发送至 contact@marketbeat.com。</em></p>
<h2>您现在应该投资 1000 美元在诺华吗？</h2>
<p>在您考虑诺华之前，您需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐的股票。MarketBeat 已识别出五只顶级分析师正在悄悄向客户推荐的股票，以便在更广泛的市场注意到之前购买……而诺华并不在名单上。</p>
<p>虽然诺华制药目前在分析师中被评为持有评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>在这里查看这五只股票</p>

诺华制药

<p>HM Payson & Co. 在第三季度显著增加了对诺华制药的持股，增幅达到 306.6%，额外购买了 10,000 股，使其总持股量达到 13,262 股，市值为 170 万美元。其他投资者，包括 Keybank 和 CW Advisors，也提高了在诺华的投资。该股票开盘价为 139.09 美元，市值为 2,938.2 亿美元。诺华报告第三季度每股收益为 2.25 美元，略低于预期，但收入同比增长了 8.5%。分析师评级各异，平均评级为 “持有”，目标价为 119.75 美元</p>

<p>HM Payson &amp; Co. increased its holdings in shares of Novartis AG (NYSE:NVS - Free Report) by 306.6% in the 3rd quarter, according to the company in its most recent filing with the Securities &amp; Exchange Commission. The fund owned 13,262 shares of the company's stock after buying an additional 10,000 shares during the quarter. HM Payson &amp; Co.'s holdings in Novartis were worth $1,701,000 at the end of the most recent reporting period.</p>
<div class="lb-trans"><p>HM Payson  Co. 在最近向证券交易委员会提交的文件中表示，在第三季度将其在诺华制药（NYSE:NVS - 免费报告）的持股增加了 306.6%。该基金在季度内购买了额外的 10,000 股后，持有该公司 13,262 股股票。HM Payson  Co. 在诺华的持股在最近的报告期末价值为 1,701,000 美元。</p>
</div><ul>
<li>Novartis' Moonshot Cancer Therapy Could Be Future Growth Driver</li>
</ul>
<div class="lb-trans"><ul>
<li>诺华的月球计划癌症疗法可能成为未来的增长驱动力</li>
</ul>
</div><p>Several other large investors have also bought and sold shares of the business. Keybank National Association OH lifted its position in shares of Novartis by 13.2% in the 2nd quarter. Keybank National Association OH now owns 49,377 shares of the company's stock worth $5,975,000 after purchasing an additional 5,742 shares during the period. Sonora Investment Management Group LLC acquired a new stake in shares of Novartis during the second quarter worth $266,000. Cypress Capital Group raised its stake in Novartis by 84.1% during the second quarter. Cypress Capital Group now owns 5,776 shares of the company's stock worth $699,000 after buying an additional 2,638 shares during the last quarter. Focus Partners Wealth lifted its holdings in Novartis by 16.8% in the first quarter. Focus Partners Wealth now owns 47,548 shares of the company's stock valued at $5,311,000 after buying an additional 6,849 shares during the period. Finally, CW Advisors LLC lifted its holdings in Novartis by 52.7% in the second quarter. CW Advisors LLC now owns 75,340 shares of the company's stock valued at $9,117,000 after buying an additional 26,009 shares during the period. 13.12% of the stock is owned by institutional investors and hedge funds.</p>
<div class="lb-trans"><p>其他几家大型投资者也买卖了该公司的股票。Keybank National Association OH 在第二季度将其在诺华的持股提高了 13.2%。Keybank National Association OH 目前持有 49,377 股该公司的股票，价值为 5,975,000 美元，在此期间又购买了 5,742 股。Sonora Investment Management Group LLC 在第二季度获得了诺华的新股份，价值为 266,000 美元。Cypress Capital Group 在第二季度将其在诺华的持股提高了 84.1%。Cypress Capital Group 目前持有 5,776 股该公司的股票，价值为 699,000 美元，在上个季度又购买了 2,638 股。Focus Partners Wealth 在第一季度将其在诺华的持股提高了 16.8%。Focus Partners Wealth 目前持有 47,548 股该公司的股票，价值为 5,311,000 美元，在此期间又购买了 6,849 股。最后，CW Advisors LLC 在第二季度将其在诺华的持股提高了 52.7%。CW Advisors LLC 目前持有 75,340 股该公司的股票，价值为 9,117,000 美元，在此期间又购买了 26,009 股。13.12% 的股票由机构投资者和对冲基金持有。</p>
</div><h2>Novartis Stock Down 0.1%</h2>
<div class="lb-trans"><h2>诺华股票下跌 0.1%</h2>
</div><p>Shares of NYSE:NVS opened at $139.09 on Tuesday. The company has a debt-to-equity ratio of 0.50, a quick ratio of 0.68 and a current ratio of 0.88. Novartis AG has a 52-week low of $96.91 and a 52-week high of $140.18. The business's 50 day simple moving average is $130.72 and its two-hundred day simple moving average is $125.69. The firm has a market cap of $293.82 billion, a P/E ratio of 19.00, a PEG ratio of 1.97 and a beta of 0.52.</p>
<div class="lb-trans"><p>NYSE:NVS 的股票周二开盘价为 139.09 美元。该公司的债务与股本比率为 0.50，速动比率为 0.68，流动比率为 0.88。诺华制药的 52 周低点为 96.91 美元，52 周高点为 140.18 美元。该公司的 50 日简单移动平均线为 130.72 美元，200 日简单移动平均线为 125.69 美元。该公司的市值为 2938.2 亿美元，市盈率为 19.00，PEG 比率为 1.97，贝塔值为 0.52。</p>
</div><ul>
<li>3 Top Big Pharma Stocks Investing Over $100 Billion in the U.S.</li>
</ul>
<div class="lb-trans"><ul>
<li>三只在美国投资超过 1000 亿美元的大型制药股</li>
</ul>
</div><p>Novartis (NYSE:NVS - Get Free Report) last issued its earnings results on Tuesday, October 28th. The company reported $2.25 earnings per share for the quarter, missing analysts' consensus estimates of $2.26 by ($0.01). Novartis had a return on equity of 41.21% and a net margin of 26.49%.The firm had revenue of $14.36 billion for the quarter, compared to analyst estimates of $13.70 billion. During the same period in the previous year, the company earned $2.06 earnings per share. Novartis's revenue for the quarter was up 8.5% compared to the same quarter last year. As a group, research analysts forecast that Novartis AG will post 8.45 EPS for the current fiscal year.</p>
<div class="lb-trans"><p>诺华（NYSE:NVS - 获取免费报告）最近于 10 月 28 日发布了其财报。该公司报告本季度每股收益为 2.25 美元，低于分析师一致预期的 2.26 美元，差额为 0.01 美元。诺华的股本回报率为 41.21%，净利润率为 26.49%。该公司本季度的收入为 143.6 亿美元，而分析师预期为 137 亿美元。在去年同期，该公司每股收益为 2.06 美元。与去年同期相比，诺华本季度的收入增长了 8.5%。整体来看，研究分析师预测诺华制药在当前财政年度将发布 8.45 美元的每股收益。</p>
</div><h2>Analyst Ratings Changes</h2>
<div class="lb-trans"><h2>分析师评级变动</h2>
</div><p>NVS has been the subject of a number of recent analyst reports. HC Wainwright downgraded Novartis to a &#34;neutral&#34; rating in a report on Monday, October 27th. Weiss Ratings restated a &#34;buy (b)&#34; rating on shares of Novartis in a research report on Monday, December 22nd. Cowen reiterated a &#34;hold&#34; rating on shares of Novartis in a report on Monday, November 10th. Bank of America raised Novartis from a &#34;neutral&#34; rating to a &#34;buy&#34; rating in a research note on Tuesday, November 25th. Finally, JPMorgan Chase &amp; Co. raised shares of Novartis from a &#34;neutral&#34; rating to an &#34;overweight&#34; rating in a research report on Monday, December 8th. One investment analyst has rated the stock with a Strong Buy rating, five have issued a Buy rating, six have issued a Hold rating and three have issued a Sell rating to the company's stock. According to data from MarketBeat.com, the company presently has an average rating of &#34;Hold&#34; and an average target price of $119.75.</p>
<div class="lb-trans"><p>NVS 最近成为多份分析师报告的主题。HC Wainwright 在 10 月 27 日的报告中将诺华的评级下调至 “中性”。Weiss Ratings 在 12 月 22 日的研究报告中重申了对诺华股票的 “买入（b）” 评级。Cowen 在 11 月 10 日的报告中重申了对诺华股票的 “持有” 评级。美国银行在 11 月 25 日的研究报告中将诺华的评级从 “中性” 上调至 “买入”。最后，摩根大通在 12 月 8 日的研究报告中将诺华的评级从 “中性” 上调至 “增持”。一位投资分析师对该股票给予了强烈买入评级，五位给予了买入评级，六位给予了持有评级，三位给予了卖出评级。根据 MarketBeat.com 的数据，该公司目前的平均评级为 “持有”，平均目标价为 119.75 美元。</p>
</div><ul>
<li>3 Momentum Stocks That Could Soar Post-Market Volatility</li>
</ul>
<div class="lb-trans"><ul>
<li>三只可能在市场波动后飙升的动量股</li>
</ul>
</div><p><strong>Get Our Latest Report on Novartis</strong></p>
<div class="lb-trans"><p><strong>获取我们关于诺华的最新报告</strong></p>
</div><h2>Novartis Profile</h2>
<div class="lb-trans"><h2>诺华简介</h2>
</div><p>(Free Report)</p>
<div class="lb-trans"><p>（免费报告）</p>
</div><p>Novartis is a Swiss multinational pharmaceutical company headquartered in Basel that researches, develops, manufactures and commercializes prescription medicines and related health-care products. Formed through the 1996 merger of Ciba-Geigy and Sandoz, Novartis operates globally and focuses on bringing therapeutics from discovery through clinical development to commercial markets worldwide.</p>
<div class="lb-trans"><p>诺华是一家总部位于巴塞尔的瑞士跨国制药公司，专注于研究、开发、生产和商业化处方药及相关医疗产品。诺华通过 1996 年 Ciba-Geigy 与 Sandoz 的合并而成立，业务遍及全球，致力于将治疗药物从发现阶段通过临床开发推向全球商业市场。</p>
</div><p>The company's activities center on innovative pharmaceuticals across several therapeutic areas, including oncology, immunology, cardiovascular and metabolic diseases, neuroscience and ophthalmology, alongside capabilities in advanced therapies such as biologics, cell and gene therapies.</p>
<div class="lb-trans"><p>该公司的活动集中在多个治疗领域的创新药物上，包括肿瘤学、免疫学、心血管和代谢疾病、神经科学和眼科，以及生物制剂、细胞和基因疗法等先进疗法的能力。</p>
</div><h2>Featured Articles</h2>
<div class="lb-trans"><h2>精选文章</h2>
</div><ul>
<li>Five stocks we like better than Novartis</li>
<li>Wall Street Stockpicker Names #1 Stock of 2026</li>
<li>Do not delete, read immediately</li>
<li>How a Family Trust May Be Able To Help Preserve Your Wealth</li>
<li>Your “birthright claim” just got activated</li>
<li>Buy this $2 Gold Stock Before January 1, 2026</li>
</ul>
<div class="lb-trans"><ul>
<li>五只我们更看好的股票超过诺华</li>
<li>华尔街股票挑选者评选 2026 年第一只股票</li>
<li>请勿删除，立即阅读</li>
<li>家族信托如何帮助保护您的财富</li>
<li>您的 “出生权索赔” 刚刚被激活</li>
<li>在 2026 年 1 月 1 日之前购买这只 2 美元的黄金股票</li>
</ul>
</div><p><strong>Want to see what other hedge funds are holding NVS?</strong> Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Novartis AG (NYSE:NVS - Free Report).</p>
<div class="lb-trans"><p><strong>想看看其他对冲基金持有的 NVS 吗？</strong> 访问 HoldingsChannel.com 获取诺华制药（NYSE:NVS - 免费报告）的最新 13F 文件和内部交易。</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPU5WUw" alt="" original-src="https://www.marketbeat.com/scripts/SECFilingChart.ashx?Prefix=NYSE&amp;Symbol=NVS"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙述科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或评论发送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Novartis Right Now?</h2>
<div class="lb-trans"><h2>您现在应该投资 1000 美元在诺华吗？</h2>
</div><p>Before you consider Novartis, you'll want to hear this.</p>
<div class="lb-trans"><p>在您考虑诺华之前，您需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Novartis wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐的股票。MarketBeat 已识别出五只顶级分析师正在悄悄向客户推荐的股票，以便在更广泛的市场注意到之前购买……而诺华并不在名单上。</p>
</div><p>While Novartis currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然诺华制药目前在分析师中被评为持有评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在这里查看这五只股票</p>
</div>

HM Payson & Co. 收购了诺华制药 $NVS 的 10,000 股股票